Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland’s Novartis works to enhance its investor appeal ahead of its market debut next month.

A Takeda spokesperson said the layoffs are not part of a larger initiative to reduce staff across the company. Rather, they are part of an effort to make sure the company is “best positioned to meet [its] current and future priorities.”

The companies said in first-quarter earnings calls that they want to restructure R&D, cut costs and shift away from high-risk drug development to focus areas.

To sharpen its focus on its core therapeutic areas, Novartis is discontinuing or licensing out 10% of its clinical development programs, the company announced Tuesday during its first-quarter financial report call with investors.

GSK has dropped both GSK3915393, an investigational celiac disease therapeutic, and GSK3878858, a Staphylococcus aureus vaccine hopeful, from its clinical development roster, the company revealed Wednesday.

GSK on Wednesday beat fourth-quarter profit and sales forecasts helped by sales of its blockbuster shingles vaccine Shingrix and unveiled an upbeat forecast for 2023.

Among the pharma company updates, Teva’s new CEO Richard Francis is confident about the company’s growth, while Y-mAbs President Thomas Gad offered more insights into the company’s 35% workforce reduction and pipeline restructuring.

Following a banner year marked by the approval and launch of its diabetes drug Mounjaro, Eli Lilly revealed at the 41st J.P. Morgan Healthcare Conference that it was preparing for another big year.

Regeneron’s oncology strategy is to improve checkpoint inhibitor treatments with combination therapies – centered around Libtayo – according to a pipeline overview presented to investors Monday morning. 

Astellas Pharma Inc. President and CEO Kenji Yasukawa, Ph.D., today announced the opening of a new late-stage clinical and commercial manufacturing facility in Sanford, N.C. The facility will allow Astellas Pharma to expand the company’s resources and team to establish a robust, global supply chain and expand its therapeutic and geographic scope.